2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-152254
    CB2R/FAAH modulator-3 2876918-67-9 99.71%
    CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The Ki values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC50 value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection.
    CB2R/FAAH modulator-3
  • HY-152265
    PARL-IN-1 3034516-68-9 98%
    PARL-IN-1 is a potent PARL inhibitor with an IC50 value of 28 nM. PARL-IN-1 inhibits PARL and leads to a robust activation of the PINK1/Parkin pathway. PARL-IN-1 promotes PINK1/Parkin-dependent mitophagy.
    PARL-IN-1
  • HY-15257A
    Mavoglurant racemate 1636881-61-2 98.44%
    Mavoglurant racemate (AFQ-056 racemate) is the racemate of Mavoglurant. Mavoglurant is a novel, non-competitive mGlu5 receptor antagonist. Mavoglurant (racemate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Mavoglurant racemate
  • HY-153091
    BMY 14802 105565-56-8 98.96%
    BMY 14802 is a sigma-1 receptor (σ1R) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM.
    BMY 14802
  • HY-153416
    QR-0217 1027786-12-4 98.47%
    QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC50 value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity.
    QR-0217
  • HY-153417
    Anti-amyloid agent-1 1396778-73-6 99.03%
    Anti-amyloid agent-1 is a potent anti-amyloid compound and inhibits amyloid aggregation. Anti-amyloid agent-1, compound ex1140 from patent WO2012119035A1, provides a useful method for amyloidosis treatment research.
    Anti-amyloid agent-1
  • HY-153430
    Aβ/tau aggregation-IN-3 1210750-32-5 99.70%
    Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC50 of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity.
    Aβ/tau aggregation-IN-3
  • HY-153463
    Diosuxentan 2305865-93-2 98%
    Diosuxentan is an inhibitor of ETA. Diosuxentan can be used in research for cardiovascular, renal and neuronal inflammation diseases.
    Diosuxentan
  • HY-153577
    WT-TTR inhibitor 1 23983-05-3 98.03%
    WT-TTR inhibitor 1 (Compound 21) is a wild-type Transthyretin (WT-TTR) inhibitor with 29.05% inhibition at 100 μM.
    WT-TTR inhibitor 1
  • HY-153822
    JG-23 2640819-75-4 99.64%
    JG-23 is a 4-chloro modified analog with ability to promote t-tau degradation. JG-23 exhibits good metabolic stability with a long T1/2 value (36 min) in mouse liver microsome assays.
    JG-23
  • HY-154436
    Anticonvulsant agent 2 75220-84-7 98%
    Anticonvulsant agent 2 is a potent and orally active anticonvulsant agent. Anticonvulsant agent 2 shows antiepileptic activity.
    Anticonvulsant agent 2
  • HY-155367
    mAChR antagonist 1 101491-79-6 99.59%
    mAChR antagonist 1 (compound 4a) is a mAChR antagonist with Ki values of 255 nM, 121 nM, 158 nM, and 255 nM for M1, M3, M4, and M5 subtype, respectively.
    mAChR antagonist 1
  • HY-155369
    BChE-IN-21 98%
    BChE-IN-21 is a potent BChE inhibitor with an IC50 of 0.14 ± 0.02 μM. BChE-IN-21 has the potential for alzheimer's disease research.
    BChE-IN-21
  • HY-155487
    JTE-151 1404380-58-0 99.34%
    JTE-151 is a RORγ inhibitor, which can suppress overactive immune response through inhibition of RORγ related to the activation of Th17 cells, making JTE-151 possible to be used in autoimmune disease research.
    JTE-151
  • HY-156023
    SIRT1 activator 2 863589-52-0 99.28%
    SIRT1 activator 2 (compound 212) is a SIRT1 activator with an ED50 of < 5 μM. SIRT1 activator 2 can be used for increasing the lifespan of a cell.
    SIRT1 activator 2
  • HY-156027
    SIRT6-IN-3 3023471-40-8 98.19%
    SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research.
    SIRT6-IN-3
  • HY-156532
    5-HT2C agonist-3 2104810-18-4 99.86%
    5-HT2C agonist-3 ((+)-19) is a selective 5-HT2C agonist (EC50: 24 nM, Ki: 78 nM). 5-HT2C agonist-3 has antipsychotic drug-like activity. 5-HT2C agonist-3 blocks Amphetamine-induced hyperactivity.
    5-HT2C agonist-3
  • HY-156666
    Casein kinase 1δ-IN-8 851396-73-1 98.0%
    Casein kinase 1δ-IN-8 (compound 494) is an inhibitor of Casein kinase 1δ, Casein kinase 1δ-IN-8 can be used in the treatment of neurodegenerative disorders such as Alzheimer's disease[1].
    Casein kinase 1δ-IN-8
  • HY-156842
    MCAAD-3 1625629-51-7
    MCAAD-3 is a near-infrared Aβ imaging probe with blood-brain barrier penetrability. MCAAD-3 has a strong affinity for Aβ polymers (Ki >106 nM) and can label Aβ plaques in the brains of transgenic mice.
    MCAAD-3
  • HY-15720B
    Glycyl H-1152 hydrochloride 913844-45-8 99.9%
    Glycyl H-1152 hydrochloride (compound 18) is a glycyl derivative of Rho-kinase inhibitors H-1152 dihydrochloride. Glycyl H-1152 hydrochloride inhibits ROCKII, Aurora A, CAMKII and PKG, with IC50s of 0.0118, 2.35, 2.57 and 3.26 μM respectively. Glycyl H-1152 hydrochloride has higher selective than H-1152 hydrochloride.
    Glycyl H-1152 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity